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Introduction {#sec001}
============

Multiple system atrophy (MSA) is a progressive neurodegenerative disease, clinically characterized by autonomic failure in addition to various combinations of parkinsonism, cerebellar ataxia, and pyramidal dysfunction. The distribution of pathologies classically encompass three functional systems in the central nervous system (CNS): the striatonigral system; the olivopontocerebellar system; and autonomic nuclei of the brainstem and spinal cord in which cytoplasmic aggregates of alpha-synuclein are primarily observed in oligodendroglia \[[@pone.0147574.ref001],[@pone.0147574.ref002]\]. However, the pathogenic mechanisms underlying this disease remain unclear, making it difficult to develop effective therapies and diagnostic biomarkers.

The *COQ2* gene encodes an enzyme essential for biogenesis of coenzyme Q10 (CoQ10). Mutations in *COQ2* have recently been found in autosomal-recessive MSA families from Japan \[[@pone.0147574.ref003]\]. Moreover, screening for *COQ2* polymorphisms in sporadic MSA cases has revealed variants conferring an increased disease risk for MSA in Japanese cohorts \[[@pone.0147574.ref003]\]. CoQ10, or ubiquinone, is a lipophilic molecule present in cell membranes that functions as an essential cofactor for electron transport in the mitochondrial respiratory chain and as an endogenous antioxidant \[[@pone.0147574.ref004]\] That discovery prompted a reconsideration of the roles of mitochondrial function and oxidative stress in the pathogenesis of this neurodegenerative disease, and also suggested the potential usefulness of CoQ10 as a blood-based diagnostic biomarker in patients with MSA.

The aim of this study was to assess and compare serum levels of CoQ10 in patients with MSA, patients with Parkinson's disease (PD) and a control population, and to evaluate whether serum levels of this antioxidant can be used to diagnose MSA.

Material and Methods {#sec002}
====================

Ethics statement, subject recruitment, and sample collection {#sec003}
------------------------------------------------------------

All study subjects provided written informed consent to participate, and the study protocols were approved by the University Ethics Committee (ERB-G-12-1, Kyoto Prefectural University, Kyoto, Japan). Study procedures were designed and performed in accordance with the Declaration of Helsinki. Patients were registered in this institute from April 2008 to August 2014. We enrolled 20 patients with MSA (MSA group) according to the current consensus criteria \[[@pone.0147574.ref005]\]. We also enrolled 20 patients with PD (PD group) according to the UK Parkinson's Disease Society Brain Bank criteria \[[@pone.0147574.ref006]\] and 20 participants with non-neurodegenerative diseases (Control group) as age-matched controls in the same registration. Of note, some participants in the MSA group were diagnosed with "possible MSA" according to the consensus criteria when clinical information and serum samples were obtained. However, we confirmed that all converted to "probable MSA" within a 3-year follow-up period. The modified Rankin Scale (mRS), which is a commonly used scale for measuring dependence \[[@pone.0147574.ref007]\], was used to grade all participants based on their medical records, because daily activities may affect levels of CoQ10 \[[@pone.0147574.ref002]\]. Since statins (3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors) reduce the biosynthesis of CoQ10 in addition to the synthesis of cholesterol \[[@pone.0147574.ref008]\], we excluded two subjects with MSA and two subjects with non-neurodegenerative diseases who were receiving statin therapy. We thus ultimately analyzed 18 samples from patients with MSA (MSA group), 20 samples from patients with PD (PD group), and 18 samples from participants with non-neurodegenerative disease (Control group). No participants were using medicines or food supplements containing CoQ10. The Control group comprised neurologically normal individuals (n = 1) or patients with various neurological disorders, including demyelinating diseases of the CNS (n = 5), epilepsy (n = 2), brain infarction (n = 3), subdural hematoma (n = 1), myositis (n = 1), normal-pressure hydrocephalus (n = 1), subarachnoid hemorrhage (n = 1), herpes zoster (n = 1), cervical spondylosis (n = 1), and neuropathy (n = 1). We avoided collecting samples for research use alone where possible. Most samples were taken when the participants were required to give blood for routine clinical diagnosis or treatment.

Serum samples were taken through venous puncture and a total of 10 ml of blood was collected in blood collection tubes with clot activator and gel separator (Terumo, Tokyo, Japan). After being allowed to clot for 15 min at room temperature, serum was separated by centrifugation for 10 min at 3000 rpm and distributed in polypropylene vials. Fresh samples obtained from the enrolled subjects were immediately stored at -80°C until used for analysis.

Measurement of CoQ10 {#sec004}
--------------------

Levels of CoQ10 and its reduced form (CoQ10H~2~) in serum were measured by SRL Inc. (Tokyo, Japan) according to the previously established method using high-performance liquid chromatography \[[@pone.0147574.ref009]\]. CoQH~2~ is easily oxidized to CoQ10 from the moment of sample extraction. Since precautions were not taken to prevent oxidation of CoQH~2~ at sample collection~,~ we evaluated the total CoQ10 (sum total of CoQ10 and CoQ10H~2~) as an index of CoQ10 deficiency \[[@pone.0147574.ref010]\]. Corrected CoQ10 levels were further defined by dividing serum CoQ10 levels by total cholesterol levels (T-Cho) (i.e., total CoQ10/T-Chol, CoQH~2~/T-Cho), because cholesterol levels influence CoQ10 levels by forming a conjugated form in blood \[[@pone.0147574.ref011]\]. Levels of serum cholesterol were enzymatically determined in our clinical laboratory.

Statistics {#sec005}
----------

The level of significance was set at P\<0.05. When data were on a continuous or ordinal scale, the homogeneity of groups was analyzed using the Mann-Whitney U test for comparing two groups and the Kruskal-Wallis for three groups. If the Kruskal-Wallis test yielded significant results, Dunn's post-hoc test was performed. The Chi-square test was used to evaluate the statistical significance of differences in categorical variables. All analyses were performed using SPSS for Windows version 23 software (IBM Japan Ltd, Tokyo, Japan).

Results {#sec006}
=======

The demographic characteristics of participants in the MSA, PD and Control groups are summarized in [Table 1](#pone.0147574.t001){ref-type="table"}. We found no significant difference in age or gender among groups: mean ages were 62.3 years in the MSA group, 63.9 years in the PD group, and 61.6 years in the Control group. Female ratios in these groups were 33.3% in the MSA group, 70% in the PD group, and 44.4% in the Control group. Mean disease duration in the MSA group (30.2 months) tended to be slightly, but not significantly, shorter than that in the PD group (67.0 months). The mRS scores did not differ significantly among the three groups: median values were 3 in the MSA group, 2 in the PD group, and 2 in the Control group. The MSA group included no familial cases of MSA, 16 patients (88.9%) with MSA-C and 2 patients (11.1%) with MSA-P ([Table 2](#pone.0147574.t002){ref-type="table"}).

10.1371/journal.pone.0147574.t001

###### Characteristics of participants in the MSA, PD and Control groups.

Data for continuous variables are expressed as mean ±standard deviation or median (maximum-minimum).

![](pone.0147574.t001){#pone.0147574.t001g}

                              MSA group (n = 18)   PD group (n = 20)   Control group (n = 18)   *P*
  --------------------------- -------------------- ------------------- ------------------------ -------
  Age (years)                 62.3±8.9             63.9±12.1           61.6±11.9                0.635
  Female/Male                 6/12                 14/6                8/10                     0.066
  Disease duration (months)   30.2±13.5            67.0±85.2           NA                       0.633
  Hoehn-Yahr stage of PD      NA                   3 (1--4)            NA                       NA
  mRS                         3 (1--4)             2 (1--4)            2 (1--3)                 0.158

NA: not available

10.1371/journal.pone.0147574.t002

###### Concentrations of serum CoQ10 and T-cho in patients with MSA.

![](pone.0147574.t002){#pone.0147574.t002g}

  Patient   Sex   Age (years)   Clinical phenotype   Disease duration(month)   mRS     CoQ10 (nmol/l)   CoQ10H~2~ (nmol/l)   Total CoQ10 (nmol/l)   T-cho (mg/dl)   Total CoQ10/T-cho ratio
  --------- ----- ------------- -------------------- ------------------------- ------- ---------------- -------------------- ---------------------- --------------- -------------------------
  1         M     57            MSA-C                14                        2       1052             79                   1131                   182             6.21
  2         M     62            MSA-C                18                        2       590              75                   665                    190             3.50
  3         F     66            MSA-C                6                         1       477              77                   554                    203             2.73
  4         F     46            MSA-C                24                        3       349              49                   398                    162             2.46
  5         F     71            MSA-C                36                        2       720              128                  848                    186             4.56
  6         F     71            MSA-C                24                        4       450              77                   527                    221             2.38
  7         F     67            MSA-C                36                        2       512              71                   583                    305             1.91
  8         F     63            MSA-C                18                        1       592              99                   691                    202             3.42
  9         F     45            MSA-P                48                        3       402              62                   464                    174             2.67
  10        F     51            MSA-C                48                        3       413              63                   476                    141             3.38
  11        M     63            MSA-C                36                        3       878              73                   951                    211             4.51
  12        F     50            MSA-P                30                        3       544              138                  682                    242             2.82
  13        M     70            MSA-C                26                        3       588              131                  719                    183             3.93
  14        F     71            MSA-C                30                        2       531              52                   583                    183             3.19
  15        M     67            MSA-C                24                        3       373              33                   406                    191             2.13
  16        F     66            MSA-C                24                        3       243              13                   256                    264             0.97
  17        F     62            MSA-C                42                        3       323              45                   368                    207             1.78
  18        M     73            MSA-C                60                        4       336              39                   375                    171             2.20
                  Mean          520.7                72.4                      593.2   201.0            3.04                                                        
                  SD            202.8                34.1                      222.6   38.5             1.23                                                        

SD: standard deviation

Levels of total CoQ10 are shown in [Fig 1A](#pone.0147574.g001){ref-type="fig"}. Mean levels of total CoQ10 were lowest in the MSA group and highest in the Control group. However, comparison of the three groups with the Kruskal-Wallis test showed no significant differences. When we compared corrected levels of total CoQ10 using the ratio of total CoQ10 to T-Cho (total CoQ10/T-Cho) among groups, the ratio was significantly lower in the MSA group than in the Control group ([Fig 1B](#pone.0147574.g001){ref-type="fig"}). Mean total CoQ10/T-Cho was higher in the PD group than in the MSA group, although statistical significance was not maintained after post-hoc analysis. An outlier was seen in the Control group, for which we could find no specific factor contributing to the extreme elevation of CoQ10 (e.g., unbalanced diet). To exclude the possibility that the statistical results were unduly influenced by this outlier, we reanalyzed the groups after removing the outlier from the data-set. Exclusion of the outlier made the mean ±standard deviation (SD) values for total CoQ10 and CoQ10/T-cho in the Control group changed from those shown in the [Table 2C](#pone.0147574.t002){ref-type="table"} to 771.1±244.9 and 4.58±1.67, respectively. The significant difference in total CoQ10/T-Cho between the MSA and Control groups was robustly confirmed even after excluding the outlier ([Fig 1C](#pone.0147574.g001){ref-type="fig"}). We also examined levels of CoQ10H~2~, which comprised the major part of total CoQ10, although these values were "only advisory", due to the possibility of sample oxidation. CoQ10H~2~/T-Cho was significantly lower in the MSA group than in the Control group, even when the outlier was excluded, similar to the findings for total CoQ10 (data not shown). Raw data for each participant are summarized in Tables [2](#pone.0147574.t002){ref-type="table"}--[4](#pone.0147574.t004){ref-type="table"}.

![(A) Scatter plot for total CoQ10 level in serum in the MSA group (n = 18), PD group (n = 20), and control group (n = 18). Mean levels of total CoQ10 were lowest in the MSA group (593.2 nmol/l) and highest in the Control group (985.3 nmol/l), although no significant difference was seen between groups. (B) Scatter plot for total CoQ10/T-Cho ratio in serum in the three groups. A significant difference was seen between groups. Post-hoc analysis showed that mean level was significantly lower in the MSA group (3.04) than in the Control group (5.92). (C) The scatter plot for total CoQ10/T-Cho ratio in serum in the three groups after excluding an outlier from the Control group.\
Similar statistical results to those shown in Graph B were also found. Bars indicate mean values. One participant in the Control group showed an extremely high total CoQ10/T-Cho ratio (Graph B). Graph C therefore shows participants after excluding this outlier. P values over the columns were obtained using the Kruskal-Wallis test. When the Kruskal-Wallis test yielded significant findings, post-hoc analysis was conducted; the results of which are shown on the right side of the graph.](pone.0147574.g001){#pone.0147574.g001}

10.1371/journal.pone.0147574.t003

###### Concentrations of serum CoQ10 and T-cho in patients with PD.

![](pone.0147574.t003){#pone.0147574.t003g}

  Patient   Sex   Age (years)   Disease duration (months)   H-Y stage/mRS   CoQ10 (nmol/l)   CoQ10H~2~ (nmol/l)   Total CoQ10 (nmol/l)   T-cho (mg/dl)   Total CoQ10/T-cho ratio
  --------- ----- ------------- --------------------------- --------------- ---------------- -------------------- ---------------------- --------------- -------------------------
  1         M     68            48                          1/1             777              81                   858                    202             4.25
  2         M     79            12                          4/4             740              89                   829                    160             5.18
  3         M     72            12                          3/3             311              38                   349                    163             2.14
  4         F     67            12                          1/2             941              79                   1020                   205             4.98
  5         M     40            24                          3/2             1299             101                  1400                   180             7.78
  6         F     66            16                          3/2             544              45                   589                    213             2.77
  7         M     75            72                          3/2             520              430                  950                    159             5.97
  8         M     53            372                         3/3             276              228                  504                    189             2.67
  9         F     66            156                         4/4             205              29                   234                    161             1.45
  10        M     41            12                          1/2             310              400                  710                    194             3.66
  11        M     56            96                          3/4             678              56                   734                    149             4.93
  12        F     78            60                          2/3             717              76                   793                    204             3.89
  13        M     67            60                          3/3             749              42                   791                    191             4.14
  14        F     65            108                         3/2             496              57                   553                    207             2.67
  15        M     67            24                          2/2             273              32                   305                    209             1.46
  16        M     47            96                          2/1             792              48                   840                    160             5.25
  17        M     74            133                         3/2             352              15                   367                    176             2.09
  18        F     50            10                          3/2             1808             29                   1837                   229             8.02
  19        M     79            12                          3/2             542              35                   577                    140             4.12
  20        M     67            4                           2/2             554              22                   576                    146             3.93
                  Mean          644.2                       96.6            740.8            181.8                4.07                                   
                  SD            382.4                       118.2           377.2            25.8                 1.84                                   

H-Y stage: Hoehn and Yahr stage in the "On" period.

10.1371/journal.pone.0147574.t004

###### Concentrations of serum CoQ10 and T-cho in the Control group.

![](pone.0147574.t004){#pone.0147574.t004g}

  Patient   Sex   Age (years)   Disease                   mRS    CoQ10 (nmol/l)   CoQ10H~2~ (nmol/l)   Total CoQ10 (nmol/l)   T-cho (mg/dl)   Total CoQ10/ T-cho ratio
  --------- ----- ------------- ------------------------- ------ ---------------- -------------------- ---------------------- --------------- --------------------------
  1         F     71            Subdural hematoma         3      678              78                   756                    169             4.47
  2         F     57            Myositis                  3      1003             231                  1234                   174             7.09
  3         F     77            NPH                       2      798              55                   853                    124             6.86
  4         F     50            Multiple sclerosis        1      420              51                   471                    199             2.37
  5         M     61            Normal                    2      1026             75                   1101                   193             5.70
  6         F     43            Neuromyelitis optica      1      4360             267                  4627                   162             28.56
  7         F     63            Subarachnoid hemorrhage   2      780              95                   875                    286             3.06
  8         F     61            Multiple sclerosis        3      436              45                   481                    137             3.51
  9         F     46            ADEM                      2      469              98                   567                    136             4.18
  10        F     76            Brain infarction          3      438              27                   465                    179             2.60
  11        M     74            Brain infarction          3      693              28                   721                    175             4.12
  12        M     71            Herpes zoster             2      700              39                   739                    156             4.74
  13        M     71            Brain infarction          2      632              64                   696                    144             4.83
  14        M     73            Epilepsy                  1      873              78                   951                    168             5.66
  15        M     63            Cervical spondylosis      3      907              87                   994                    239             4.16
  16        M     41            Neuropathy                2      485              30                   515                    205             2.51
  17        F     46            Multiple sclerosis        1      439              140                  579                    147             3.93
  18        M     65            Epilepsy                  1      1066             45                   1111                   135             8.23
                  Mean          900.2                     85.2   985.3            173.8                5.92                                   
                  SD            890.6                     66.6   939.4            40.4                 5.88                                   

NPH, normal-pressure hydrocephalus; ADEM, acute disseminated encephalomyelitis

Note: Multiple sclerosis, neuromyelitis optica, and ADEM are collectively referred to as demyelinating diseases of the central nervous system in the text.

Discussion {#sec007}
==========

The present study showed decreased total CoQ10/T-Cho ratios in MSA compared with controls, although differences in total CoQ10 levels between groups were not significant. Since CoQ10 is distributed into lipoproteins in the liver and released into the circulation because of its hydrophobicity \[[@pone.0147574.ref012]\], serum CoQ10 concentrations are highly dependent on lipoprotein levels. Levels of CoQ10 normalized to T-Cho levels have thus been accepted as a better biomarker of CoQ10 deficiency than non-corrected CoQ10 levels \[[@pone.0147574.ref009]\]. To the best of our knowledge, this is the first study to report an association between decreased levels of serum CoQ10 and risk of MSA. Our findings suggest that serum CoQ10 has potential as a biomarker in the diagnosis of MSA. The results correspond to the facts that functionally impaired variants of the *COQ2* gene are associated with decreased levels of CoQ10 in brain tissue and an increased risk of MSA \[[@pone.0147574.ref003]\].

Leaving aside the obvious limitation of the small sample size that may have undermined the reliability of the results, we would like to note the bias caused by the predominance of the MSA-C subtype as a possible confounder. Phenotype distributions for MSA differ between populations. The MSA-P subtype predominates among Caucasian MSA patients, while MSA-C is more common in the Japanese population \[[@pone.0147574.ref013],[@pone.0147574.ref014]\]. The percentage of patients exhibiting the MSA-C subtype in our study (88.9%) was similar to that in a previous study of Japanese patients with clinically diagnosed MSA (83.8%) \[[@pone.0147574.ref015]\]. According to a study of primary CoQ10 deficiency, concentrations of CoQ10 in the human brain were lowest in the cerebellum, which may thus be selectively vulnerable to CoQ10 deficiency \[[@pone.0147574.ref016]\]. Such findings suggest that compromised *COQ2* function and/or decreased CoQ10 concentrations may contribute to cerebellar degeneration in MSA. This idea is also supported by the fact that the ratio of patients with MSA-C to those with MSA-P was higher among carriers of deleterious *COQ2* variants than among non-carriers \[[@pone.0147574.ref003]\]. Considering such observations, our findings might hold true only for patients with MSA-C, and not for those with MSA-P, although the two participants with MSA-P in this study did not show marked differences in CoQ10/T-Cho ratio from the rest of the MSA group ([Table 2](#pone.0147574.t002){ref-type="table"}).

In future, large-scale case-control studies including adequate numbers of MSA-P patients are needed to confirm our findings and to elucidate whether decreased ratios of serum total CoQ10/T-Cho ratio are also found in patients with MSA-P.
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